|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123599 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-28 10:39:09 |
|
注册时间: Date of Registration: |
2026-04-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
国产与进口品牌主动脉球囊反搏泵系统的有效性及安全性对照研究 |
|
Public title: |
Comparative Study on Effectiveness and Safety of Domestic versus Imported Intra-Aortic Balloon Pump Counterpulsation Systems |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
国产与进口品牌主动脉球囊反搏泵系统的有效性及安全性对照研究 |
|
Scientific title: |
Comparative Study on Effectiveness and Safety of Domestic versus Imported Intra-Aortic Balloon Pump Counterpulsation Systems |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李冬冬 |
研究负责人: |
向定成 |
|
Applicant: |
Dongdong Li |
Study leader: |
Dingcheng Xiang |
|
申请注册联系人电话: Applicant telephone: |
+86 139 2274 0191 |
研究负责人电话:
Study leader's |
+86 136 0900 8024 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
winterlid@foxmail.com |
研究负责人电子邮件: Study leader's E-mail: |
dcxiang@foxmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市越秀区流花路111号 |
研究负责人通讯地址: |
广东省广州市越秀区流花路111号 |
|
Applicant address: |
General Hospital of Southern Theatre Command, PLA, Guangzhou, China |
Study leader's address: |
General Hospital of Southern Theatre Command, PLA, Guangzhou, China |
|
申请注册联系人邮政编码: Applicant postcode: |
510010 |
研究负责人邮政编码: Study leader's postcode: |
510010 |
|
申请人所在单位: |
中国人民解放军南部战区总医院 |
||
|
Applicant's institution: |
General Hospital of Southern Theatre Command, PLA |
||
|
研究负责人所在单位: |
中国人民解放军南部战区总医院 |
||
|
Affiliation of the Leader: |
General Hospital of Southern Theatre Command, PLA |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
NZLLKZ2026051 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南部战区总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the General Hospital of the Southern Theater Command |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-02 00:00:00 | ||
|
伦理委员会联系人: |
周泉 |
||
|
Contact Name of the ethic committee: |
Quan Zhou |
||
|
伦理委员会联系地址: |
广东省广州市越秀区流花路111号 |
||
|
Contact Address of the ethic committee: |
General Hospital of Southern Theatre Command, PLA, Guangzhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8865 4445 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国人民解放军南部战区总医院 |
||||||||||||||||||||||
|
Primary sponsor: |
General Hospital of Southern Theatre Command, PLA |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市越秀区流花路111号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
General Hospital of Southern Theatre Command, PLA, Guangzhou, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-raised funds |
||||||||||||||||||||||
|
研究疾病: |
心源性休克、复杂冠脉病变PCI手术需要IABP辅助循环支持 |
||||||||||||||||||||||
|
Target disease: |
Cardiogenic shock/Complex coronary artery disease PCI surgery requires IABP-assisted circulatory support |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机交叉对照 |
||||||||||||||||||||||
|
Study design: |
Cross-over |
||||||||||||||||||||||
|
研究目的: |
1.通过与进口品牌对照,评价国产首家上市的主动脉球囊反搏泵(IABP)设备及球囊导管对患者循环支持的疗效及安全性;2.同时比较不同品牌设备使用兼容球囊导管的疗效差异,为临床IABP进行循环支持时使用兼容产品提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.By comparing with imported brands, the efficacy and safety of the first domestic Aortic balloon Pump(IABP) device and balloon catheter on the market in providing circulatory support to patients were evaluated. 2. At the same time, compare the therapeutic effect differences of compatible balloon catheters using different brand devices to provide a basis for the use of compatible products when providing circulatory support for clinical IABP. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.急性心肌梗死或爆发性心肌炎或扩张性心肌病合并心源性休克(心源性休克在B期或C期)或复杂冠脉病变PCI手术需要IABP辅助循环支持的患者或其他原因需要IABP辅助循环支持的患者; 2.窦性心律; 3.年龄14~85岁。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Patients with acute myocardial infarction or fulminant myocarditis or dilated cardiomyopathy complicated 1.with cardiogenic shock (cardiogenic shock in stage B or C) or complex coronary artery disease who need IABP-assisted circulatory support during PCI surgery, or patients who need IABP-assisted circulatory support for other reasons; 2.Sinus rhythm; 3. Age: 14 to 85 years old. |
||||||||||||||||||||||
|
排除标准: |
1.溶栓后患者; 2.抗凝禁忌症; 3.股动脉穿刺失败; 4.心肺复苏后心电不稳定; 5.主动脉瓣中度以上返流; 6.主动脉夹层或主动脉瘤; 7.严重感染; 8.年龄<14岁或>85岁; 9.计划或预期需要联合使用多种循环辅助支持治疗者; 10.研究者认为不宜入选。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients after thrombolysis; 2. Contraindications for anticoagulation; 3. Femoral artery puncture failed; 4. Unstable electrocardiogram after cardiopulmonary resuscitation; 5. Moderate or severe aortic valve regurgitation; 6. Aortic dissection or aortic aneurysm; 7. Severe infection; 8. Age <14 years old or >85 years old; 9. Those who plan or expect to need the combined use of multiple circulatory adjuvant support treatments; 10. The researchers believe that it is not suitable for selection. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-15 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-01 00:00:00 至 To 2026-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用简单随机化(Simple Randomization),由组长单位统计学专业人员使用PASS 2021 统计软件产生随机序列,按 1:1 比例将受试者随机分配至 A 组或 B 组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Simple randomization was used. The random sequence was generated by statisticians from the leading research institute using PASS 2021 software, with a 1:1 allocation ratio to Group A or Group B. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
开放标签 |
|
Blinding: |
Open label |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过邮箱向研究负责人申请获取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the research is completed, apply to the research leader for access via email. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
一、数据采集 1. 所有临床数据均来自住院病历、实验室检查报告、床旁监护数据、超声报告、IABP 设备运行记录等原始资料。 2. 由经过 GCP 及研究方案培训的研究护士 / 研究者,在规定时间窗内将数据实时、准确、完整录入电子数据采集系统(EDC)。 3. 关键数据(血流动力学指标、不良事件、器械使用记录)由研究者双人核对,确保与原始资料一致。 4. 数据采集全程遵循真实、及时、准确、完整、可溯源原则。 二、数据管理 1. 设立数据管理小组,由组长单位统计师与数据管理员负责。 2. 电子数据系统设置逻辑核查、范围核查、必填项核查,自动生成数据疑问(Query),由研究中心及时答疑。 3. 数据管理过程包括:数据接收→录入→核查→疑问解答→修正→锁定。 4. 数据锁定后不可修改,锁定后由统计师进行统计分析。 5. 所有数据加密存储、权限分级管理,保障受试者隐私与数据安全。 6. 研究数据保存至临床研究结束后至少 3 年。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. Data Collection All clinical data were obtained from original sources, including hospital medical records, laboratory reports, bedside monitoring data, echocardiography reports, and IABP device operation records.Specially trained investigators and research nurses collected and entered data into the Electronic Data Capture (EDC) system timely, accurately and completely.Key data (hemodynamics, adverse events, device usage) were double-checked by investigators to ensure consistency with source documents. 2. Data Management A dedicated data management team (statisticians and data managers from the leading site) was responsible for data management.The EDC system performed valid checks, range checks, and logic checks; queries were generated and resolved in a timely manner.Data management included data entry, verification, query resolution, and final data lock.After data lock, no further changes were allowed.All data were encrypted and stored securely with access control to protect privacy.Data will be retained for at least 3 years after study completion. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |